XINGANJIANG
873167
Sichuan Goldstone
300434
Hangzhou Huasu Technology
301157
Suzhou Harmontronics Automation Technology
688022
Xinjiang Tianshan Animal Husbandry Bio-engineering
300313
CN Stock MarketDetailed Quotes
605116 Aurisco Pharmaceutical
- 20.56
- +0.26+1.28%
Trading Jan 6 13:17 CST
8.35BMarket Cap24.51P/E (TTM)
20.85High20.25Low9.54KlotVolume20.25Open20.30Pre Close19.66MTurnover0.24%Turnover Ratio28.84P/E (Static)406.20MShares26.9952wk High3.83P/B8.17BFloat Cap17.1152wk Low22.33Limit Up397.51MShs Float30.71Historical High18.27Limit Down2.96%Amplitude9.41Historical Low0.22Dividend TTM20.60Avg Price3.56KlotAsk1.07%Div YieldTTM100Lot Size5.57KlotBid
Aurisco Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 17.97%1.09B | 32.21%730.66M | 11.08%335.62M | 25.24%1.26B | 19.97%922.53M | 8.59%552.65M | 38.07%302.14M | 25.48%1.01B | 30.53%768.96M | 26.67%508.94M |
| Operating revenue | 17.97%1.09B | 32.21%730.66M | 11.08%335.62M | 25.24%1.26B | 19.97%922.53M | 8.59%552.65M | 38.07%302.14M | 25.48%1.01B | 30.53%768.96M | 26.67%508.94M |
| Other operating revenue | ---- | -57.23%2.91M | ---- | 18.90%8.59M | ---- | 99.57%6.8M | ---- | 149.00%7.23M | ---- | 54.67%3.41M |
| Total operating cost | 10.40%764.64M | 17.59%514.1M | -2.81%237.89M | 25.92%957.3M | 24.65%692.61M | 19.63%437.18M | 44.60%244.77M | 22.39%760.23M | 25.79%555.66M | 18.01%365.44M |
| Operating cost | 11.10%454.67M | 13.18%314.04M | -5.49%155.46M | 14.12%556.56M | 5.95%409.24M | 12.33%277.47M | 69.51%164.48M | 19.34%487.68M | 28.80%386.26M | 14.16%247.01M |
| Operating tax surcharges | 0.54%6.42M | 9.41%4.7M | 50.79%3.67M | 28.93%9.84M | 19.14%6.39M | 40.10%4.29M | 70.18%2.44M | 11.40%7.63M | 10.38%5.36M | -4.02%3.07M |
| Operating expense | 32.85%89.33M | 166.73%68.98M | 124.84%24.13M | 152.81%100.78M | 134.92%67.24M | 32.11%25.86M | 15.85%10.73M | 34.22%39.86M | 31.98%28.62M | 35.31%19.58M |
| Administration expense | -0.50%120.7M | -2.94%79.43M | -1.38%37.34M | 25.33%169.71M | 39.65%121.3M | 47.99%81.84M | 31.12%37.86M | 27.39%135.41M | 17.59%86.86M | 19.17%55.3M |
| Financial expense | -61.11%-11.85M | -125.59%-18.5M | -429.60%-11.64M | 40.37%-16.47M | 77.46%-7.36M | 45.41%-8.2M | 628.89%3.53M | -8,331.33%-27.61M | -5,223.22%-32.64M | -1,298.99%-15.02M |
| -Interest expense (Financial expense) | 278.96%6.18M | -20.50%1.01M | 10.09%590.31K | 171.25%2.74M | --1.63M | --1.27M | 171.87%536.18K | 57.16%1.01M | ---- | ---- |
| -Interest Income (Financial expense) | -318.35%-12.88M | -362.84%-9.87M | -572.36%-7.82M | -274.80%-16.53M | 7.86%-3.08M | 20.39%-2.13M | -12.05%-1.16M | 46.65%-4.41M | -11.56%-3.34M | 9.21%-2.68M |
| Research and development | 10.01%105.37M | 17.04%65.44M | 12.50%28.93M | 16.73%136.89M | 17.98%95.78M | 0.74%55.91M | -20.09%25.72M | 69.09%117.26M | 98.93%81.19M | 98.47%55.5M |
| Credit Impairment Loss | 4.92%-3.5M | -1,450.58%-3.07M | 161.28%596.14K | -17.37%-4.9M | 31.82%-3.68M | 107.97%227.61K | -602.61%-972.77K | -398.72%-4.17M | -499.81%-5.4M | -481.98%-2.85M |
| Asset Impairment Loss | ---- | ---- | ---- | 2.24%-7.66M | ---- | --15.99K | ---- | ---7.83M | ---- | ---- |
| Other net revenue | -93.25%2.39M | -59.25%1.02M | 69.74%2.72M | 488.09%25.5M | 1,371.96%35.41M | -36.85%2.5M | -58.56%1.6M | -157.46%-6.57M | -69.50%2.41M | -38.65%3.95M |
| Fair value change income | 153.80%660.35K | ---- | ---- | ---- | -7,355.96%-1.23M | -9,103.85%-2.22M | ---- | ---- | -90.52%16.92K | -82.56%24.63K |
| Invest income | -93.07%2.27M | 82.69%1.51M | 215.35%476.85K | 2,774.18%31.72M | 12,169.69%32.82M | 387.64%824.64K | ---413.4K | -275.20%-1.19M | -41.65%267.45K | -42.05%169.11K |
| Asset deal income | -136.76%-468.92K | 39.93%-212.38K | -627.30%-286.29K | -2.18%-1.53M | 4,052.92%1.28M | -480.70%-353.57K | -222.38%-39.36K | -277.18%-1.5M | 90.07%-32.27K | 434.78%92.87K |
| Other revenue | -44.95%3.43M | -30.05%2.8M | -36.16%1.93M | -3.22%7.86M | -17.57%6.23M | -38.67%4M | -16.84%3.03M | -16.80%8.12M | 21.43%7.56M | 23.27%6.52M |
| Operating profit | 22.89%326.08M | 84.44%217.57M | 70.33%100.45M | 37.07%330.73M | 23.01%265.33M | -20.00%117.96M | 10.38%58.97M | 24.61%241.28M | 38.96%215.7M | 49.61%147.45M |
| Add:Non operating Income | 7,205.56%521.71K | 11,102.20%498.72K | 823.54%9.24K | -3.65%11.37K | 38.02%7.14K | 66.55%4.45K | 24.91%1K | -75.31%11.8K | -80.86%5.17K | -80.54%2.67K |
| Less:Non operating expense | 274.75%2.02M | 563.49%1.7M | 488.04%1.35M | 209.15%1.66M | 0.90%538.36K | -36.81%256.52K | 367.58%229.58K | -67.62%536.53K | -63.83%533.55K | 7.81%405.96K |
| Total profit | 22.58%324.58M | 83.82%216.37M | 68.71%99.11M | 36.69%329.08M | 23.06%264.8M | -19.95%117.71M | 10.06%58.74M | 25.38%240.75M | 39.93%215.18M | 49.75%147.05M |
| Less:Income tax cost | 27.17%40.79M | 33.16%27.78M | 29.85%16.92M | 23.21%40.01M | 8.74%32.07M | -32.42%20.86M | 1.50%13.03M | 36.85%32.47M | 42.68%29.49M | 102.87%30.87M |
| Net profit | 21.94%283.79M | 94.73%188.59M | 79.79%82.18M | 38.79%289.07M | 25.34%232.73M | -16.64%96.85M | 12.77%45.71M | 23.77%208.28M | 39.50%185.68M | 40.01%116.18M |
| Net profit from continuing operation | 21.94%283.79M | 94.73%188.59M | 79.79%82.18M | 38.79%289.07M | 25.34%232.73M | -16.64%96.85M | 12.77%45.71M | 23.77%208.28M | 39.50%185.68M | 40.01%116.18M |
| Less:Minority Profit | ---- | ---- | ---- | 86.97%-349.87K | 125.57%182.26K | 269.36%952.35K | 47.29%-166.98K | -520.88%-2.69M | -73.60%-712.71K | ---562.32K |
| Net profit of parent company owners | 22.04%283.79M | 96.66%188.59M | 79.14%82.18M | 37.19%289.42M | 24.76%232.55M | -17.85%95.9M | 12.30%45.88M | 25.04%210.96M | 39.60%186.39M | 40.69%116.74M |
| Earning per share | ||||||||||
| Basic earning per share | 22.81%0.7 | 91.67%0.46 | 81.82%0.2 | 36.54%0.71 | 23.91%0.57 | -17.24%0.24 | 10.00%0.11 | 23.81%0.52 | 39.39%0.46 | 38.10%0.29 |
| Diluted earning per share | 19.30%0.68 | 91.67%0.46 | 81.82%0.2 | 36.54%0.71 | 23.91%0.57 | -17.24%0.24 | 10.00%0.11 | 23.81%0.52 | 39.39%0.46 | 38.10%0.29 |
| Other composite income | -72.33%360.09K | -73.57%64.01K | 116.32%34.43K | 948.80%21.99M | -41.10%1.3M | -76.68%242.19K | 23.78%-211.03K | 624.97%2.1M | 1,114.43%2.21M | 576.87%1.04M |
| Other composite income of parent company owners | -72.33%360.09K | -73.57%64.01K | 116.32%34.43K | 948.80%21.99M | -41.10%1.3M | -76.68%242.19K | 23.78%-211.03K | 624.97%2.1M | 1,114.43%2.21M | 576.87%1.04M |
| Total composite income | 21.42%284.16M | 94.31%188.66M | 80.70%82.22M | 47.86%311.06M | 24.56%234.03M | -17.17%97.09M | 13.02%45.5M | 25.31%210.38M | 41.39%187.89M | 41.63%117.21M |
| Total composite income of parent company owners | 21.51%284.16M | 96.23%188.66M | 80.04%82.22M | 46.16%311.41M | 23.99%233.85M | -18.37%96.14M | 12.55%45.67M | 26.59%213.06M | 41.49%188.6M | 42.31%117.78M |
| Total composite income of minority owners | ---- | ---- | ---- | 86.97%-349.87K | 125.57%182.26K | 269.36%952.35K | 47.29%-166.98K | -520.88%-2.69M | -73.60%-712.71K | ---562.32K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
